Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6, and 15 months, the samples were c...
Main Authors: | Bożena Karolewicz, Agata Górniak, Dominik M. Marciniak, Igor Mucha |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/11/7/304 |
Similar Items
-
Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01) -
Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01) -
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01) -
Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
by: Shreya Agrawal, et al.
Published: (2023-01-01) -
OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)